Scholarlink

<p>We report a single-arm phase 2 trial of pembrolizumab in advanced malignant peripheral nerve sheath tumors at Oslo University Hospital. Long-lasting response in 1 of 8 patients was associated with high tumor density of PD-1<sup>+</sup>CD8<sup>+</sup> T cells. Mixed response in another patient was associated with PD-L1 expression, and PD-L1 was mostly not co-expressed on CD68<sup>+</sup> macrophages or CD8<sup>+</sup> cells. The study was prematurely closed due to a slow accrual rate.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pembrolizumab in advanced malignant peripheral nerve sheath tumors: a single-arm phase 2 trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月27日

查看全文
  • Anita Sveen,
  • Christian H. Bergsland,
  • Barbara Niederdorfer,
  • Audun E. Berstad,
  • Bodil Bjerkehagen,
  • Kjetil Boye,
  • Tormod K. Guren,
  • Ragnhild A. Lothe

摘要

We report a single-arm phase 2 trial of pembrolizumab in advanced malignant peripheral nerve sheath tumors at Oslo University Hospital. Long-lasting response in 1 of 8 patients was associated with high tumor density of PD-1+CD8+ T cells. Mixed response in another patient was associated with PD-L1 expression, and PD-L1 was mostly not co-expressed on CD68+ macrophages or CD8+ cells. The study was prematurely closed due to a slow accrual rate.